ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 2083

New Treatment Approach of Rheumatoid Arthritis Based On Inhibition of Cyclin Dependent Kinase-9

Annelie Hellvard1, Lutz Zeitlmann2, Ulrich Heiser3, André Niestroj3, Hans-Ulrich Demuth3, Jan Potempa4 and Piotr Mydel1, 1Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, 2Ingenium Pharmaceuticals GmbH, Martinsried, Germany, 3Probiodrug AG, Halle/Saale, Germany, 4Microbiology Department, Jagiellonian University, Krakow, Poland

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: animal models and treatment, Apoptosis, rheumatoid arthritis

Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cyclin dependent kinase-9 (cdk-9) is transcription regulator of the carboxyterminal domain of RNA polymerase II. The usage of pan-cdk inhibitors such as flavopiridol has proven to be efficient in the treatment of cancer, targeting both cell cycle- and transcription-regulating cyclin dependent kinases. In this study we sought to investigate the effect of specific small molecular inhibitor of cell cycle independent cdk-9 development and progression of  collagen induced arthritis.

Methods: DBA/1 mice were immunized with 100ug bovine collagen type II at day 0 and day 21. During experiment mice were treated orally with highly specific cdk-9 inhibitors (compound 1 and compound 2), either 10mg/kg daily or 10mg/kg and 30mg/kg twice a week, respectively. Clinical scoring was performed every second day during experiment and was followed by histological evaluation at end of experiment. Protein expression of Mcl-1 and survivin in spleens was determined by western immunoblotting. Flow cytometric analysis of regulatory T cells in spleens from arthritic mice following daily treatment as well as 7day treatment of healthy NMRI mice was performed. 

Peripheral blood mononuclear cells were incubated with compound 1 and induction of apoptosis, as well as protein and RNA expression of Mcl-1 was investigated. Caspase-3 activity, LDH activity and Mcl-1 protein expression was assessed in human monocyte derived macrophages following incubation with compound 1.

Results: Mice treated with compound compound 1 or compound 2 showed striking delay in onset as well as significant reduction in severity of arthritis. This effect was shown, not only in daily treatment but also in bi-weekly regime. Western blot of spleens showed decreased level of Mcl-1 in a dose dependent manner, whereas survivin levels were significantly increased. Flow cytometric analysis of splenocytes in arthritic- and healthy mice treated with inhibitors showed an increase in frequency of regulatory T cells.

Cdk-9 inhibition in peripheral blood mononuclear cells resulted in loss of Mcl-1 expression both on protein and RNA level with a subsequent increase in apoptosis. Down-regulation of Mcl-1 was also observed in monocyte derived macrophages with an activation of caspase-3.

Conclusion: This study provides clear results that inhibition of cdk-9 is working in an immunomodulatory manner, independent of high survivin expression and may in the future serve as an alternative treatment, not only of cancer, but also of autoimmune- and inflammatory diseases.


Disclosure:

A. Hellvard,
None;

L. Zeitlmann,

Ingenium Pharmaceuticals GmbH,

3;

U. Heiser,

Probiodrug AG,

3;

A. Niestroj,

Probiodrug AG,

3;

H. U. Demuth,

Probiodrug AG,

3;

J. Potempa,
None;

P. Mydel,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-treatment-approach-of-rheumatoid-arthritis-based-on-inhibition-of-cyclin-dependent-kinase-9/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology